World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 10 July 2015
Main ID:  EUCTR2011-004720-35-NO
Date of registration: 26/01/2015
Prospective Registration: Yes
Primary sponsor: Karolinska Institutet
Public title: A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment.
Scientific title: A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment. - NORD-STAR
Date of first enrolment: 04/05/2015
Target sample size: 800
Recruitment status: Authorised-recruitment may be ongoing or finished
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-004720-35
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes Randomised: yes Open: yes Single blind: no Double blind: no Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: no Number of treatment arms in the trial: 4  
Phase: 
Countries of recruitment
Denmark Finland Norway Sweden
Contacts
Name: Unit for Clinical Therapy Research   
Address:  Nobelsväg 5, Solna 171 77 Stockholm Sweden
Telephone: 0046852480000
Email: info@ki.fi
Affiliation:  Karolinska Institutet
Name: Unit for Clinical Therapy Research   
Address:  Nobelsväg 5, Solna 171 77 Stockholm Sweden
Telephone: 0046852480000
Email: info@ki.fi
Affiliation:  Karolinska Institutet
Key inclusion & exclusion criteria
Inclusion criteria:
1. Subject is =18 years of age.
2. Subject has a diagnosis of RA as defined by the newly established ACR/EULAR criteria, 2010 (Appendix D). (Patients should also be classified according to the 1987-revised ACR-classification criteria, without this being an inclusion criteria) (Appendix C).
3. <24 months from arthritis symptom debut (symptom duration will be registered).
4. Subject must have DAS28 (CRP) > 3.2.
5. = 2 swollen joints AND = 2 tender joints.
6. Subject must fulfill one of the following three criteria: RF positive OR ACPA positive OR CRP >10 mg/L.
7. Female subject is either not of childbearing potential (postmenopausal, surgically sterile etc.), or is of childbearing potential and practicing one of the following methods of birth control throughout the study and for 150 days after study completion:
• Intrauterine device (IUD)
• Contraceptives (oral, parenteral, patch) for three months prior to study drug administration)
• A vasectomized partner
8. Female subjects of childbearing potential must have a negative serum pregnancy test at the Screening visit.
9. Subject is judged to be in good general health as determined by the principal investigator based upon the results of medical history, laboratory profile, physical examination, chest X-ray (CXR), and 12-lead electrocardiogram (ECG) performed at Screening.
10. Subjects must be able and willing to provide written informed consent and comply with the requirements of this study protocol.
11. Subjects must be able and willing to self-administer s.c. injections or have a qualified person available to administer s.c. injections.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 400
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 400

Exclusion criteria:
1. Subject has been previously treated with disease modifying antirheumatic drugs (DMARDs) for rheumatic diseases.
2. Current active inflammatory joint disease other than RA.
3. Subjects has had a dose of prednisone (or equivalent) >7.5 mg/day or has had a dose change within the preceding 4 weeks.
4. Subject has been treated with intra-articular or parenteral administration of corticosteroids in the preceding 4 weeks. Inhaled corticosteroids for stable medical conditions are allowed.
5. Subject has undergone joint surgery within the preceding two months (at joints to be assessed within the study).
6. Subject has chronic arthritis diagnosed before age 17 years.
7. Subject has a history of an allergic reaction or significant sensitivity to constituents of study drugs.
8. Subject has been treated with any investigational drug within one month prior to screening visit.
9. Active infection of any kind (excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization within 4 weeks of screening.
10. Subject has a poorly controlled medical condition, such as uncontrolled diabetes, unstable heart disease, congestive heart failure, recent cerebrovascular accidents and any other condition which, in the opinion of the investigator, would put the subject at risk by participation in the study.
11. Subject has a history of clinically significant hematologic (e.g., severe anemia, leukopenia, thrombocytopenia), renal or liver disease (e.g., fibrosis, cirrhosis, hepatitis).
12. Subject has history of neurologic symptoms suggestive of central nervous system (CNS) demyelinating disease and/or diagnosis of central demyelinating disease.
13. Subject has history of cancer or lymphoproliferative disease. Allowable exceptions:
a. Successfully treated cutaneous squamous cell or basal cell carcinoma
b. Localized carcinoma in situ of the cervix
c. Curatively treated malignancy (treatment terminated) > 5 years prior to screening
14. Subject has a history of listeriosis, histoplasmosis, untreated TB, persistent chronic infections, or recent active infections requiring hospitalization or treatment with intravenous (iv) anti-infectives within 30 days or oral anti-infectives within 14 days prior to the BL visit.
15. Subjects will be evaluated for latent TB infection with a PPD or QuantiFERON test and X-ray. Subjects with evidence for latent TB will not be enrolled but first assessed according to local guidelines.
16. Subject is known to have immune deficiency, history of Human Immunodeficiency Virus (HIV) or is otherwise severely immunocompromised.
17. Female subject who is pregnant or breast-feeding or considering becoming pregnant during the study or within 150 days after the last dose of study medication.
18. Subject has a history of clinically significant drug or alcohol usage in the last year.
19. Subject has a chronic widespread pain syndrome.
20. Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study.
21. Subject is unwilling to comply with the study protocol.
22. Screening clinical laboratory analyses show any of the following abnormal laboratory results:
a. Aspartate transaminase (AST) or alanine transaminase (ALT) > 1.75 times upper limit of normal (ULN).
b. Positive serum human chorionic gonadotropin (hCG).
c. Positive tests for hepatitis B surface antigen (HBsAg) or hepatitis C serology indicative of current infection.
d. Creatinine levels > 2x the ULN. If creatinin


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Rheumatoid arthritis (RA)
MedDRA version: 18.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Intervention(s)

Trade Name: Cimzia
Pharmaceutical Form: Injection
INN or Proposed INN: CERTOLIZUMAB PEGOL
CAS Number: 428863-50-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-

Trade Name: Orencia
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: ABATACEPT
CAS Number: 332348-12-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 125-

Trade Name: RoActemra
Pharmaceutical Form: Infusion
CAS Number: 375823-41-9
Other descriptive name: TOCILIZUMAB
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 20-

Trade Name: Methotrexate

Pharmaceutical Form: Tablet
INN or Proposed INN: METHOTREXATE
CAS Number: 59-05-2
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 20-25

Trade Name: Metex
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: METHOTREXATE
Other descriptive name: METHOTREXATE DISODIUM
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 20-25

Trade Name: Imurel
Pharmaceutical Form: Tablet
INN or Proposed INN: IMUREL
CAS Number: 446-86-6
Other descriptive name: AZATHIOPRINE
Concentration unit: mg/kg milligram(s)/kilogram
Concentration type: range
Concentration number: 2.0-2.5

Trade Name: Arava
Pharmaceutical Form: Tablet
INN or Proposed INN: LEFLUNOMIDE
CAS Number: 75706-12-6
Other descriptive name: Arava
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 10-20

Product Name: Salazopyrin EN
Pharmaceutical Form: Tablet
INN or Proposed INN: Salazopyrin EN
Other descriptive name: SULFASALAZINE
Concentration unit: g gram(s)
Concentration type: up to
Concentration number: 2-

Trade Name: Plaquenil
Product Name: Plaquenil
Pharmaceutical Form: Tablet
INN or Proposed INN: Plaquenil
CAS Number: 747-36-4
Other descriptive name: HYDROXYCHLOROQUINE SULFATE
Concentration unit: mg milligram(s)
Concent
Primary Outcome(s)
Main Objective: The objective of this study is to assess and compare 1) the proportion of subjects who achieve remission with active conventional therapy (ACT) versus three different biologic therapies; and 2) two alternative de-escalation strategies in patients who respond to first-line therapy.
Primary end point(s): A. Treatment Part 1: The primary efficacy outcome is the proportion of patients in remission at week 24 from baseline according to CDAI.

B. Treatment Part 2: The primary efficacy outcome is the proportion of patients in remission according to CDAI, at the time point 24 weeks after the dose was first reduced.

C. The primary efficacy outcome is the progression of total Sharp van der Heijde score after 56 weeks from baseline.
Secondary Objective: To identify biomarkers that are predictive of treatment response and successful drug tapering.
Timepoint(s) of evaluation of this end point: A. 24 weeks from baseline
B. 24 weeks after the dose was first reduced
C. 56 weeks from baseline
Secondary Outcome(s)
Secondary end point(s): Clinical outcomes
1. CDAI/SDAI/2010 ACR/EULAR remission at all time points
2. ACR20/ACR50/ACR70/ACR-hybrid
3. DAS28 (based on ESR)
•values
•DAS28-ESR based disease categories
•EULAR responses
4. DAS28-CRP
•values
•DAS28-CRP based disease categories
•EULAR responses
5. SDAI, CDAI values
6. Core set variables (66/68 joint count)
7. FACIT fatigue score and VAS fatigue
8. WPAI
9. EQ5D
10. HAQ
11. SF36
12. Patient VAS for general health and pain assessment
13. Physician VAS for general health assessment

Radiographic outcomes
Change in modified total Sharp score, modified Sharp erosion score, modified Sharp joint space narrowing score, the proportion of patients without radiographic progression (defined as change in total modified Sharp score <= 0) and the reduction of predicted progression according to the published ”POPERA” model.
Semi-quantitative ultrasonography score (0-3), both grey-scale and power-Doppler, in 36 joints + extensor carpi ulnaris tendon and tibialis posterior tendon
Timepoint(s) of evaluation of this end point: Clinical outcomes are relevant at all time points (vistits between 2-12 weeks of duration throughout the study)

Radiographic outcomes are relevant at all time points (vistits between 2-12 weeks of duration throughout the study)

Secondary ID(s)
2011-004720-35-SE
NCT01491815
NORD-STAR
Source(s) of Monetary Support
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history